title: Survival in medically treated patients with homozygous beta-thalassemia.
abstract: BACKGROUND
  The prognosis of patients with homozygous beta-thalassemia (thalassemia major) has been improved by transfusion and iron-chelation therapy. We analyzed outcome and prognostic factors among patients receiving transfusions and chelation therapy who had reached the age at which iron-induced cardiac disease, the most common cause of death, usually occurs.
  
  
  METHODS
  Using the duration of life without the need for either inotropic or antiarrhythmic drugs as a measure of survival without cardiac disease, we studied 97 patients born before 1976 who were treated with regular transfusions and chelation therapy. We used Cox proportional-hazards analysis to assess the effect of prognostic factors and life-table analysis to estimate freedom from cardiac disease over time.
  
  
  RESULTS
  Of the 97 patients, 59 (61 percent) had no cardiac disease; 36 (37 percent) had cardiac disease, and 18 of them had died. Univariate analysis demonstrated that factors affecting cardiac disease-free survival were age at the start of chelation therapy (P < 0.001), the natural log of the serum ferritin concentration before chelation therapy began (P = 0.01), the mean ferritin concentration (P < 0.001), and the proportion of ferritin measurements exceeding 2500 ng per milliliter (P < 0.001). With stepwise Cox modeling, only the proportion of ferritin measurements exceeding 2500 ng per milliliter affected cardiac disease-free survival (P < 0.001). Patients in whom less than 33 percent of the serum ferritin values exceeded 2500 ng per milliliter had estimated rates of survival without cardiac disease of 100 percent after 10 years of chelation therapy and 91 percent after 15 years.
  
  
  CONCLUSIONS
  The prognosis for survival without cardiac disease is excellent for patients with thalassemia major who receive regular transfusions and whose serum ferritin concentrations remain below 2500 ng per milliliter with chelation therapy.
authors.affiliation: Haemoglobinopathy Program, Hospital for Sick Children, Toronto, ON, Canada.
authors.forename: N F
authors.initials: NF
authors.lastname: Olivieri
authors.forename: D G
authors.initials: DG
authors.lastname: Nathan
authors.forename: J H
authors.initials: JH
authors.lastname: MacMillan
authors.forename: A S
authors.initials: AS
authors.lastname: Wayne
authors.forename: P P
authors.initials: PP
authors.lastname: Liu
authors.forename: A
authors.initials: A
authors.lastname: McGee
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: G
authors.initials: G
authors.lastname: Koren
authors.forename: A R
authors.initials: AR
authors.lastname: Cohen
mesh_terms: D000328:Adult; D001803:Blood Transfusion; D015913:Chelation Therapy; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron; D008297:Male; D011379:Prognosis; D016016:Proportional Hazards Models; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000401:mortality* / Q000628:therapy
chemical_list: D005293:Ferritins; D007501:Iron